4 studies found for:    15728811 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
2 Recruiting BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Condition: Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Bevacizumab
3 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Positive EGFR Mutation
Intervention: Drug: BIBW 2992
4 Recruiting Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW 2992
Conditions: Skin Rash;   Lung Cancer
Intervention: Drug: Tetracycline

Indicates status has not been verified in more than two years